

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4976815

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
BIOPHARMA CREDIT PLC	05/02/2018
RECEIVING PARTY DATA	
Name:	BRAINTREE LABORATORIES, INC.
Street Address:	60 COLUMBIAN STREET WEST
City:	BRAINTREE
State/Country:	MASSACHUSETTS
Postal Code:	02185
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	14774018
Application Number:	15885046
Application Number:	15669749
Application Number:	15594109
Application Number:	15456497
Application Number:	14173144
CORRESPONDENCE DATA	
Fax Number:	(312)706-9000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312-701-8623
Email:	rassmus@mayerbrown.com, mdecember@mayerbrown.com
Correspondent Name:	RICHARD M. ASSMUS
Address Line 1:	P.O. BOX 2828
Address Line 4:	CHICAGO, ILLINOIS 60690-2828
ATTORNEY DOCKET NUMBER:	17553669
NAME OF SUBMITTER:	RICHARD M. ASSMUS
SIGNATURE:	/RMA/
DATE SIGNED:	05/24/2018
This document serves as an Oath/Declaration (37 CFR 1.63).	

Total Attachments: 5

source=Limited Release of Security Interest in Patents#page1.tif

source=Limited Release of Security Interest in Patents#page2.tif

source=Limited Release of Security Interest in Patents#page3.tif

source=Limited Release of Security Interest in Patents#page4.tif

source=Limited Release of Security Interest in Patents#page5.tif

LIMITED RELEASE OF SECURITY INTEREST IN PATENTS

THIS LIMITED RELEASE OF SECURITY INTEREST IN PATENTS (this "Limited Release") is made as of May 2, 2018 ("Effective Date") by and among BioPharma Credit PLC, a public limited company incorporated under the laws of England and Wales, as collateral agent (in such capacity, "Grantee"), Braintree Laboratories, Inc., a Massachusetts corporation with its principal office at 60 Columbian Street West, P.O. Box 850929, Braintree, MA 02185-0929 ("Grantor"), and Sebela BT Holdings, Inc., a Delaware corporation with its principal office at 645 Hembree Pkwy., Suite I, Roswell, GA 30076 ("Borrower").

WHEREAS, Borrower and Grantee are parties to that certain Loan Agreement dated as of April 20, 2018 (the "Loan Agreement"). Terms capitalized but not defined herein shall have the meanings assigned to such terms in the Loan Agreement;

WHEREAS, pursuant to the terms and conditions of that certain Guaranty and Security Agreement among Borrower, Grantor, Grantee and the other parties thereto, dated as of May 1, 2018, Grantor and Grantee entered into a Patent Security Agreement (the "Patent Security Agreement"), whereby Grantor granted to Grantee a continuing security interest in all of Grantor's right, title and interest in, to and under the Patent Collateral (as defined in the Patent Security Agreement), including, without limitation, the patents and patent applications set forth on Schedule A attached hereto (the "Subject Patents"), to secure the payment of all amounts owed by Grantor under the Loan Agreement; and

WHEREAS, in connection with the Group Restructuring, Grantor has assigned all of its right, title and interest in and to all of the Subject Patents to Borrower and Borrower has subsequently assigned the same to Sebela International Development Limited, a Bermuda company, effective as of the Effective Date.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantee hereby terminates, cancels and releases any and all security interests it has against the Subject Patents and only in the Subject Patents, and discharges, quit claims and relinquishes unto the Grantor (in each case without recourse and without any representation or warranty) any and all right, title and interest it has in and to the Subject Patents (and only the Subject Patents) under the Patent Security Agreement.

Grantee shall, at Grantor's expense, take all further actions, and provide to Grantor, Grantor's successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by Grantor to more fully and effectively effectuate the purposes of this Limited Release.

This Limited Release shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York, without regard to any principles of conflicts of law that could require the application of the law of any other jurisdiction.


* * * * *

IN WITNESS WHEREOF, Grantee has caused this Limited Release to be executed by its duly authorized representative as of the Effective Date.

BIOPHARMA CREDIT PLC, as Collateral Agent

By: Pharmakon Advisors, LP,
its Investment Manager

By: Pharmakon Management I, LLC,
its General Manager

By: 
Name: Martin Friedman
Title: Principal

SCHEDULE A
SUBJECT PATENTS

<u>Name of Entity</u>	<u>Country</u>	<u>Title</u>	<u>Filing Date</u>	<u>Status</u>	<u>Application Number</u>
Braintree Laboratories, Inc.	United States of America	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/09/2015	Published	14/774018
Braintree Laboratories, Inc.	Patent Cooperation Treaty	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	03/14/2014	Published	PCT/US2014/028805
Braintree Laboratories, Inc.	Australia	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	08/07/2015	Pending	2014227598.0
Braintree Laboratories, Inc.	Brazil	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	08/18/2015	Published	BR112015019776-0
Braintree Laboratories, Inc.	Canada	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	08/27/2015	Pending	2903283.0
Braintree Laboratories, Inc.	China (People's Republic)	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/14/2015	Published	2014800152727.0
Braintree Laboratories, Inc.	Colombia	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	10/13/2015	Published	15242343.0

Braintree Laboratories, Inc.	Ecuador	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	10/13/2015	Published	IEPI-2015-43310
Braintree Laboratories, Inc.	Eurasian Patent Organization	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/23/2015	Published	201591568.0
Braintree Laboratories, Inc.	European Patent Convention	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/03/2015	Published	14722461.2
Braintree Laboratories, Inc.	Hong Kong	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	03/04/2016	Published	16102502.9
Braintree Laboratories, Inc.	India	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	08/21/2015	Published	5101/CHENP/2015
Braintree Laboratories, Inc.	Israel	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/09/2015	Published	241367.0
Braintree Laboratories, Inc.	Japan	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/09/2015	Published	2016-502905
Braintree Laboratories, Inc.	Mexico	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/09/2015	Published	MX/A/2015/012109
Braintree Laboratories, Inc.	Peru	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	09/10/2015	Published	001930-2015

Braintree Laboratories, Inc.	United States of America	DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF	31-Jan-2018	Pending	15/885,046
Braintree Laboratories, Inc.	United States of America	SOLID ORAL FORMULATIONS FOR CLEANSING A COLON AND METHODS OF USING THE SAME	08/04/2017	Published	15/669,749
Braintree Laboratories, Inc.	United States of America	METHOD OF ADMINISTERING LACTITOL TO REDUCE PLASMA CONCENTRATION OF LACTITOL	05/12/2017	Pending	15/594,109
Braintree Laboratories, Inc.	United States of America	SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF	03/11/2017	Pending	15/456,497
Braintree Laboratories, Inc.	European Patent Convention	SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF	04/11/2017	Pending	15840422.8
Braintree Laboratories, Inc.	United States of America	SULFATE TABLET COMPOSITIONS AND METHODS OF USING THE SAME	02/05/2014	Pending	14/173,144
Braintree Laboratories, Inc.	Patent Cooperation Treaty	SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF	9/11/2015	Published	PCT/US2015/049571
Braintree Laboratories, Inc.	Patent Cooperation treaty	SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF	4/11/2017	Published	PCT/US2015/049571